BCAL Diagnostics LimitedASX: BDX

BCAL Expands Breast Cancer Biomarker Program

· Issued by BCAL Diagnostics Limited via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

BCAL Diagnostics Limited has announced the expansion of its breast cancer biomarker program and advancements in scientific validation, including receiving ethics approval for multiomic assay development. The company has published a manuscript in a peer-reviewed journal detailing its lipidomics framework for breast cancer diagnostics and submitted another paper currently under revision. These developments enhance BCAL's clinical development pathway and broaden its research capabilities for future diagnostic applications.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement 17 November 2026 BCAL expands breast cancer biomarker program and advances scientific validation Highlights • Human Research Ethics Committee approval received to expand BCAL’s existing breast cancer sample collection and analysis program to include multiomic assay development....

BCAL Diagnostics Limited on 6ix

Earlier from BCAL Diagnostics

Later from BCAL Diagnostics

All BCAL Diagnostics news releases